INT J ENDOCRINOL 润色咨询

International Journal of Endocrinology

出版年份:2009 年文章数:1942 投稿命中率: 开通期刊会员,数据随心看

出版周期:Irregular 自引率:3.7% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0<br>经验分享:投稿3个多月,催了一次,回复说找不到审稿人,让自己推荐审稿人,也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:甲状腺<br>经验分享:2023年6月中旬投稿,10月初 一审给大修,11月下旬返修后显示under review,两周后变成pending approval,到目前持续了16天了没有改变,不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投,要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向:糖尿病;临床<br>经验分享:15天 还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了,状态还是V1(Academic Editor Invited),难道杂志还没找到审稿人吗?这种情况正常吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向:甲状腺<br>经验分享:投稿9天,还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval,大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月,两个审稿人,意见都比较友好,也好改,给了大修,刚刚提交上去,希望老天保佑接收吧,今年一篇也没接收,太衰了,求转运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956425, encodeId=f2729564252a, content=我的投出去半个月了,还是审核中,并且没有安排编辑,请问这是正常情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bc5479837, createdName=ms3000000547008505, createdTime=Tue Apr 13 03:48:30 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:编辑比较友好<br>2021.7月投稿<br>2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=)]
    2023-07-02 我爱写歌词 来自山东省

    审稿速度:3.0
    经验分享:投稿3个多月,催了一次,回复说找不到审稿人,让自己推荐审稿人,也是醉了。

    3

    展开3条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0<br>经验分享:投稿3个多月,催了一次,回复说找不到审稿人,让自己推荐审稿人,也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:甲状腺<br>经验分享:2023年6月中旬投稿,10月初 一审给大修,11月下旬返修后显示under review,两周后变成pending approval,到目前持续了16天了没有改变,不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投,要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向:糖尿病;临床<br>经验分享:15天 还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了,状态还是V1(Academic Editor Invited),难道杂志还没找到审稿人吗?这种情况正常吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向:甲状腺<br>经验分享:投稿9天,还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval,大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月,两个审稿人,意见都比较友好,也好改,给了大修,刚刚提交上去,希望老天保佑接收吧,今年一篇也没接收,太衰了,求转运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956425, encodeId=f2729564252a, content=我的投出去半个月了,还是审核中,并且没有安排编辑,请问这是正常情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bc5479837, createdName=ms3000000547008505, createdTime=Tue Apr 13 03:48:30 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:编辑比较友好<br>2021.7月投稿<br>2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=)]
    2023-12-19 12112347m62(暂无昵称) 来自浙江省

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向:甲状腺
    经验分享:2023年6月中旬投稿,10月初 一审给大修,11月下旬返修后显示under review,两周后变成pending approval,到目前持续了16天了没有改变,不知道能不能接收~

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0<br>经验分享:投稿3个多月,催了一次,回复说找不到审稿人,让自己推荐审稿人,也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:甲状腺<br>经验分享:2023年6月中旬投稿,10月初 一审给大修,11月下旬返修后显示under review,两周后变成pending approval,到目前持续了16天了没有改变,不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投,要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向:糖尿病;临床<br>经验分享:15天 还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了,状态还是V1(Academic Editor Invited),难道杂志还没找到审稿人吗?这种情况正常吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向:甲状腺<br>经验分享:投稿9天,还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval,大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月,两个审稿人,意见都比较友好,也好改,给了大修,刚刚提交上去,希望老天保佑接收吧,今年一篇也没接收,太衰了,求转运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956425, encodeId=f2729564252a, content=我的投出去半个月了,还是审核中,并且没有安排编辑,请问这是正常情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bc5479837, createdName=ms3000000547008505, createdTime=Tue Apr 13 03:48:30 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:编辑比较友好<br>2021.7月投稿<br>2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=)]
    2022-01-18 120a0830m36暂无昵称

    被Clinical endocrinology 推荐转投,要不要接受。。。

    5

    展开5条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0<br>经验分享:投稿3个多月,催了一次,回复说找不到审稿人,让自己推荐审稿人,也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:甲状腺<br>经验分享:2023年6月中旬投稿,10月初 一审给大修,11月下旬返修后显示under review,两周后变成pending approval,到目前持续了16天了没有改变,不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投,要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向:糖尿病;临床<br>经验分享:15天 还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了,状态还是V1(Academic Editor Invited),难道杂志还没找到审稿人吗?这种情况正常吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向:甲状腺<br>经验分享:投稿9天,还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval,大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月,两个审稿人,意见都比较友好,也好改,给了大修,刚刚提交上去,希望老天保佑接收吧,今年一篇也没接收,太衰了,求转运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956425, encodeId=f2729564252a, content=我的投出去半个月了,还是审核中,并且没有安排编辑,请问这是正常情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bc5479837, createdName=ms3000000547008505, createdTime=Tue Apr 13 03:48:30 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:编辑比较友好<br>2021.7月投稿<br>2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=)]
    2023-10-18 ms1000001042631374 来自江西省

    偏重的研究方向:糖尿病;临床
    经验分享:15天 还在AE invited....

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0<br>经验分享:投稿3个多月,催了一次,回复说找不到审稿人,让自己推荐审稿人,也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:甲状腺<br>经验分享:2023年6月中旬投稿,10月初 一审给大修,11月下旬返修后显示under review,两周后变成pending approval,到目前持续了16天了没有改变,不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投,要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向:糖尿病;临床<br>经验分享:15天 还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了,状态还是V1(Academic Editor Invited),难道杂志还没找到审稿人吗?这种情况正常吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向:甲状腺<br>经验分享:投稿9天,还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval,大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月,两个审稿人,意见都比较友好,也好改,给了大修,刚刚提交上去,希望老天保佑接收吧,今年一篇也没接收,太衰了,求转运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956425, encodeId=f2729564252a, content=我的投出去半个月了,还是审核中,并且没有安排编辑,请问这是正常情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bc5479837, createdName=ms3000000547008505, createdTime=Tue Apr 13 03:48:30 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:编辑比较友好<br>2021.7月投稿<br>2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=)]
    2021-12-30 大道至简111

    投稿2个半月了,状态还是V1(Academic Editor Invited),难道杂志还没找到审稿人吗?这种情况正常吗?

    3

    展开3条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0<br>经验分享:投稿3个多月,催了一次,回复说找不到审稿人,让自己推荐审稿人,也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:甲状腺<br>经验分享:2023年6月中旬投稿,10月初 一审给大修,11月下旬返修后显示under review,两周后变成pending approval,到目前持续了16天了没有改变,不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投,要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向:糖尿病;临床<br>经验分享:15天 还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了,状态还是V1(Academic Editor Invited),难道杂志还没找到审稿人吗?这种情况正常吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向:甲状腺<br>经验分享:投稿9天,还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval,大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月,两个审稿人,意见都比较友好,也好改,给了大修,刚刚提交上去,希望老天保佑接收吧,今年一篇也没接收,太衰了,求转运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956425, encodeId=f2729564252a, content=我的投出去半个月了,还是审核中,并且没有安排编辑,请问这是正常情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bc5479837, createdName=ms3000000547008505, createdTime=Tue Apr 13 03:48:30 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:编辑比较友好<br>2021.7月投稿<br>2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=)]
    2023-05-20 cq2019 来自湖北省

    偏重的研究方向:甲状腺
    经验分享:投稿9天,还没有指派学术编辑

    4

    展开4条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0<br>经验分享:投稿3个多月,催了一次,回复说找不到审稿人,让自己推荐审稿人,也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:甲状腺<br>经验分享:2023年6月中旬投稿,10月初 一审给大修,11月下旬返修后显示under review,两周后变成pending approval,到目前持续了16天了没有改变,不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投,要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向:糖尿病;临床<br>经验分享:15天 还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了,状态还是V1(Academic Editor Invited),难道杂志还没找到审稿人吗?这种情况正常吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向:甲状腺<br>经验分享:投稿9天,还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval,大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月,两个审稿人,意见都比较友好,也好改,给了大修,刚刚提交上去,希望老天保佑接收吧,今年一篇也没接收,太衰了,求转运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956425, encodeId=f2729564252a, content=我的投出去半个月了,还是审核中,并且没有安排编辑,请问这是正常情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bc5479837, createdName=ms3000000547008505, createdTime=Tue Apr 13 03:48:30 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:编辑比较友好<br>2021.7月投稿<br>2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=)]
    2023-08-09 Peter忘记我 来自河北省

    20多天一直是pending approval,大概需要等多久

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0<br>经验分享:投稿3个多月,催了一次,回复说找不到审稿人,让自己推荐审稿人,也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:甲状腺<br>经验分享:2023年6月中旬投稿,10月初 一审给大修,11月下旬返修后显示under review,两周后变成pending approval,到目前持续了16天了没有改变,不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投,要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向:糖尿病;临床<br>经验分享:15天 还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了,状态还是V1(Academic Editor Invited),难道杂志还没找到审稿人吗?这种情况正常吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向:甲状腺<br>经验分享:投稿9天,还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval,大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月,两个审稿人,意见都比较友好,也好改,给了大修,刚刚提交上去,希望老天保佑接收吧,今年一篇也没接收,太衰了,求转运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956425, encodeId=f2729564252a, content=我的投出去半个月了,还是审核中,并且没有安排编辑,请问这是正常情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bc5479837, createdName=ms3000000547008505, createdTime=Tue Apr 13 03:48:30 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:编辑比较友好<br>2021.7月投稿<br>2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=)]
    2022-10-23 120a6ac7m01(暂无昵称)

    审了三个月,两个审稿人,意见都比较友好,也好改,给了大修,刚刚提交上去,希望老天保佑接收吧,今年一篇也没接收,太衰了,求转运!

    7

    展开7条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0<br>经验分享:投稿3个多月,催了一次,回复说找不到审稿人,让自己推荐审稿人,也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:甲状腺<br>经验分享:2023年6月中旬投稿,10月初 一审给大修,11月下旬返修后显示under review,两周后变成pending approval,到目前持续了16天了没有改变,不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投,要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向:糖尿病;临床<br>经验分享:15天 还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了,状态还是V1(Academic Editor Invited),难道杂志还没找到审稿人吗?这种情况正常吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向:甲状腺<br>经验分享:投稿9天,还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval,大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月,两个审稿人,意见都比较友好,也好改,给了大修,刚刚提交上去,希望老天保佑接收吧,今年一篇也没接收,太衰了,求转运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956425, encodeId=f2729564252a, content=我的投出去半个月了,还是审核中,并且没有安排编辑,请问这是正常情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bc5479837, createdName=ms3000000547008505, createdTime=Tue Apr 13 03:48:30 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:编辑比较友好<br>2021.7月投稿<br>2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=)]
    2021-04-13 ms3000000547008505

    我的投出去半个月了,还是审核中,并且没有安排编辑,请问这是正常情况吗?

    9

    展开9条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2145939, encodeId=5b372145939df, content=审稿速度:3.0<br>经验分享:投稿3个多月,催了一次,回复说找不到审稿人,让自己推荐审稿人,也是醉了。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJp0sD8Z3gbQmV24MRDY7wn75cHicnUffTMDfpXJuEV3sNaw70NtickSVHcMDAxV6UZ7ROKn78GcWwA/132, createdBy=034f2309606, createdName=我爱写歌词, createdTime=Sun Jul 02 10:20:42 CST 2023, time=2023-07-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2175813, encodeId=cfa321e5813ae, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:甲状腺<br>经验分享:2023年6月中旬投稿,10月初 一审给大修,11月下旬返修后显示under review,两周后变成pending approval,到目前持续了16天了没有改变,不知道能不能接收~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/5aea3dc4251f1ef471c5d5f5a2e6ca51/40d445eef080ed392185b807ff427f40.jpg, createdBy=a8932225910, createdName=12112347m62(暂无昵称), createdTime=Tue Dec 19 14:25:06 CST 2023, time=2023-12-19, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1185640, encodeId=6e08118564089, content=被Clinical endocrinology 推荐转投,要不要接受。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=42, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Jan 18 15:33:16 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2163606, encodeId=320f216360695, content=偏重的研究方向:糖尿病;临床<br>经验分享:15天 还在AE invited...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8cf08742257, createdName=ms1000001042631374, createdTime=Wed Oct 18 20:24:25 CST 2023, time=2023-10-18, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=1178938, encodeId=cc1f11e8938b8, content=投稿2个半月了,状态还是V1(Academic Editor Invited),难道杂志还没找到审稿人吗?这种情况正常吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201115/937b8f20c0774529b47007cd6100793f/bded1fa23ee5467e9d40e08b043a7890.jpg, createdBy=24402559221, createdName=大道至简111, createdTime=Thu Dec 30 18:39:57 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2138051, encodeId=847b2138051ba, content=偏重的研究方向:甲状腺<br>经验分享:投稿9天,还没有指派学术编辑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=5fd51628848, createdName=cq2019, createdTime=Sat May 20 19:04:50 CST 2023, time=2023-05-20, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2151959, encodeId=3e0821519598a, content=20多天一直是pending approval,大概需要等多久, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLialg5UCybAynKPP9tvWhTj2404jIJgEN2uu4oQLlXDiaRwI904aiaUahh3Cwtndog3oJfFXVicsTEPg/132, createdBy=6edb2240528, createdName=Peter忘记我, createdTime=Wed Aug 09 16:07:26 CST 2023, time=2023-08-09, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2095526, encodeId=762220955269d, content=审了三个月,两个审稿人,意见都比较友好,也好改,给了大修,刚刚提交上去,希望老天保佑接收吧,今年一篇也没接收,太衰了,求转运!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/19/eccf35eff026d776b97c650c7e9da159.jpg, createdBy=4ba62196925, createdName=120a6ac7m01(暂无昵称), createdTime=Sun Oct 23 14:27:40 CST 2022, time=2022-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956425, encodeId=f2729564252a, content=我的投出去半个月了,还是审核中,并且没有安排编辑,请问这是正常情况吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=56bc5479837, createdName=ms3000000547008505, createdTime=Tue Apr 13 03:48:30 CST 2021, time=2021-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2090861, encodeId=b4a6209086121, content=审稿速度:3.0 | 投稿命中率:75.0<br>经验分享:编辑比较友好<br>2021.7月投稿<br>2021.10月接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3fd5464124, createdName=ms5000000380461904, createdTime=Wed Sep 28 18:44:42 CST 2022, time=2022-09-28, status=1, ipAttribution=)]
    2022-09-28 ms5000000380461904

    审稿速度:3.0 | 投稿命中率:75.0
    经验分享:编辑比较友好
    2021.7月投稿
    2021.10月接受

    0

共115条页码: 1/12页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分